-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18 Sep 2025 20:00 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
18 Sep 2025 11:30 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
17 Sep 2025 03:45 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
16 Sep 2025 20:02 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
03 Dec 2024 12:30 GMT
… the trial. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, … has shown that omecamtiv mecarbil increases cardiac contractility … omecamtiv mecarbil, demonstrated a statistically significant effect of treatment with omecamtiv mecarbil …
-
Human medicines European public assessment report (EPAR): Kinharto, Omecamtiv mecarbil, Date of refusal: 07/05/2024, Status: Withdrawn application
31 May 2024 14:36 GMT
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Kinharto could not be authorised for the treatment of chronic (long-term) …
-
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
31 Aug 2025 16:10 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
ESC 2025: study gives insight into OM and red cell distribution width
30 Aug 2025 11:16 GMT
… MD PhD presented data on omecamtiv mecarbil (OM) and red cell distribution … : ulacamten in Phase II and omecamtiv mecarbil in Phase III.
-
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
30 Aug 2025 07:18 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics to Participate in September Investor Conferences
27 Aug 2025 20:00 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in …